1. Home
  2. VRAX vs SONM Comparison

VRAX vs SONM Comparison

Compare VRAX & SONM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • SONM
  • Stock Information
  • Founded
  • VRAX 2013
  • SONM 1999
  • Country
  • VRAX United Kingdom
  • SONM United States
  • Employees
  • VRAX N/A
  • SONM N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • SONM Telecommunications Equipment
  • Sector
  • VRAX Health Care
  • SONM Telecommunications
  • Exchange
  • VRAX Nasdaq
  • SONM Nasdaq
  • Market Cap
  • VRAX 17.2M
  • SONM 17.8M
  • IPO Year
  • VRAX 2022
  • SONM 2019
  • Fundamental
  • Price
  • VRAX $1.97
  • SONM $3.23
  • Analyst Decision
  • VRAX
  • SONM
  • Analyst Count
  • VRAX 0
  • SONM 0
  • Target Price
  • VRAX N/A
  • SONM N/A
  • AVG Volume (30 Days)
  • VRAX 4.9M
  • SONM 11.0K
  • Earning Date
  • VRAX 11-26-2024
  • SONM 11-13-2024
  • Dividend Yield
  • VRAX N/A
  • SONM N/A
  • EPS Growth
  • VRAX N/A
  • SONM N/A
  • EPS
  • VRAX N/A
  • SONM N/A
  • Revenue
  • VRAX $156,419.00
  • SONM $56,744,000.00
  • Revenue This Year
  • VRAX $5,169.18
  • SONM N/A
  • Revenue Next Year
  • VRAX $66.97
  • SONM $107.78
  • P/E Ratio
  • VRAX N/A
  • SONM N/A
  • Revenue Growth
  • VRAX 1727.11
  • SONM N/A
  • 52 Week Low
  • VRAX $0.60
  • SONM $2.32
  • 52 Week High
  • VRAX $9.00
  • SONM $10.70
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 46.98
  • SONM 45.46
  • Support Level
  • VRAX $1.92
  • SONM $3.30
  • Resistance Level
  • VRAX $2.50
  • SONM $3.56
  • Average True Range (ATR)
  • VRAX 0.22
  • SONM 0.22
  • MACD
  • VRAX 0.01
  • SONM -0.05
  • Stochastic Oscillator
  • VRAX 26.97
  • SONM 13.88

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About SONM Sonim Technologies Inc.

Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the United States, and to Bell, Rogers, and Telus Mobility in Canada. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.

Share on Social Networks: